- cafead   Jun 21, 2023 at 11:02: PM
via Aldeyra Therapeutics Inc has received a Complete Response Letter from the FDA for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection) for primary vitreoretinal lymphoma (PVRL).
article source
article source